吉西他滨膀胱灌注化疗在非肌层浸润性膀胱癌术后患者中的应用效果

Application effect of intravesical chemotherapy with gemcitabine in postoperative patients with non-muscle-invasive bladder cancer

目的探讨吉西他滨膀胱灌注化疗在非肌层浸润性膀胱癌术后患者中的应用效果。方法根据治疗方法的不同将120例非肌层浸润性膀胱癌患者分为对照组和观察组,每组60例。所有患者均进行手术治疗,对照组患者术后给予吡柔比星膀胱灌注化疗,观察组患者术后给予吉西他滨膀胱灌注化疗。比较两组患者的临床疗效、肿瘤标志物[血清癌胚抗原(CEA)、尿纤维蛋白原降解产物(FDP)]水平、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]及不良反应发生情况。结果观察组患者的疾病控制率为88.33%,明显高于对照组患者的68.33%,差异有统计学意义(P﹤0.01)。治疗后,两组患者血清CEA、尿FDP水平均低于本组治疗前,观察组患者血清CEA、尿FDP水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者躯体功能、角色功能、社会功能、总体健康评分均高于本组治疗前,观察组患者躯体功能、角色功能、社会功能、总体健康评分均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论吉西他滨膀胱灌注化疗可提高非肌层浸润性膀胱癌术后患者的临床疗效和生活质量,降低肿瘤标志物水平,且安全性良好。

Objective To investigate the application effect of intravesical chemotherapy with gemcitabine in postoperative patients with non-muscle-invasive bladder cancer.Method A total of 120 patients with non-muscle-invasive bladder cancer were divided into control group and observation group according to different treatment methods,with 60 cases in each group.All patients received surgical treatment,patients in the control group received postoperative intravesical chemotherapy with pirarubicin,patients in the observation group received postoperative intravesical chemotherapy with gemcitabine.The clinical efficacy,tumor markers[serum carcinoembryonic antigen(CEA),urinary fibrinogen degradation product(FDP)],quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)]and adverse reactions were compared between the two groups.Result The disease control rate of the observation group was 88.33%,which was significantly higher than 68.33%of the control group,and the difference was statistically significant(P<0.01).After treatment,the serum CEA and urinary FDP levels in the two groups were lower than those before treatment,and the serum CEA and urinary FDP levels in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of physical function,role function,social function and overall health in the two groups were higher than those before treatment,and the scores in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Intravesical chemotherapy with gemcitabine can improve the clinical efficacy and quality of life of postoperative patients with non-muscle-invasive bladder cancer,reduce the levels of tumor markers,and has good safety.